Investigational drug · Phase 2
CVL237
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "CVL237"
First trial start
2023
Dec 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CVL237", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- PTEN Loss or Low Expression
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CVL237" as an intervention, largest first.
Convalife (Shanghai) Co., Ltd.Industry
NCT07446049 · 180 participants (planned) · Start May 1, 2026 · Primary completion Jan 9, 2028
Drug: CVL237 tablets · For: Locally Advanced or Metastatic Solid Tumors; PTEN Loss or Low Expression
Convalife (Shanghai) Co., Ltd.Industry
NCT06183736 · 98 participants (planned) · Start Dec 20, 2023 · Primary completion Jun 30, 2025
Drug: CVL237 tablets · For: Advanced Solid Tumors
Sites: Beijing, China
- CVL237 Tablets for APDS/PASLIPivotal-lookingStatus unknown
Convalife (Shanghai) Co., Ltd.Industry
NCT06293716 · 35 participants (planned) · Start Mar 30, 2024 · Primary completion Dec 29, 2025
Drug: CVL237 tablets; CVL237 placebo tablets · For: PI3K and P110delta Hyperactivation Syndrome
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.